Literature DB >> 28926732

Multifunctional mesoporous ZrO2 encapsulated upconversion nanoparticles for mild NIR light activated synergistic cancer therapy.

Lili Feng1, Shili Gai1, Fei He1, Yunlu Dai1, Chongna Zhong1, Piaoping Yang2, Jun Lin3.   

Abstract

Desirable nanosystem that could not only deliver drugs safely and effectively into tumor sites, but also be expected to serve as photosensitizer to realize the photodynamic therapeutic function, would be of great significance in the synergistic cancer therapy. To perform this task, a multifunctional nanosystem has been developed for markedly enhanced cancer therapeutic efficacy by loading chemotherapy agent (doxorubicin hydrochloride, DOX) and photosensitive drug chlorin e6 (Ce6) into the channels of mesoporous zirconium dioxide (ZrO2) layer which coats on Nd3+-doped upconversion nanoparticles (UCNPs). As a temperature sensitive phase change material (PCM), the loaded tetradecanol was served as switch for control release of DOX and reactive oxygen species (ROS) in the condition of enhanced temperature triggered by the near infrared (NIR) light irradiation. The hyperthermia generated from the UCNPs cores exposed to NIR laser could raise the temperature of tumor location to 47.8 °C. The as-synthesized UCNPs@ZrO2-Ce6/DOX/PCM nanosystem demonstrates an excellent in vivo synergistic effect by administrating into U14 tumor-bearing mice via intravenous injection, under mild NIR laser irradiation (0.5 W cm-2, 5 min break after 5 min irradiation). In a word, our experimental results indicate that the finely designed UCNPs@ZrO2-Ce6/DOX/PCM may act as an ideal nanoplatform for multiple imaging guided tumor therapy.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Phase change material; Photodynamic therapy; Upconversion; Zirconium dioxide

Mesh:

Substances:

Year:  2017        PMID: 28926732     DOI: 10.1016/j.biomaterials.2017.09.011

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  pH-Sensitive morphological transitions in polymeric tadpole assemblies for programmed tumor therapy.

Authors:  Cunfeng Song; Tongtong Lin; Qiang Zhang; S Thayumanavan; Lei Ren
Journal:  J Control Release       Date:  2018-11-01       Impact factor: 9.776

2.  NIR-Activated Polydopamine-Coated Carrier-Free "Nanobomb" for In Situ On-Demand Drug Release.

Authors:  Minghui Li; Xuetan Sun; Ning Zhang; Wei Wang; Yang Yang; Huizhen Jia; Wenguang Liu
Journal:  Adv Sci (Weinh)       Date:  2018-05-09       Impact factor: 16.806

3.  Artificially controlled degradable nanoparticles for contrast switch MRI and programmed cancer therapy.

Authors:  Tianyang Yun; Yuxin Liu; Shaoqiong Yi; Qi Jia; Yang Liu; Jing Zhou
Journal:  Int J Nanomedicine       Date:  2018-10-24

Review 4.  Nanomedicine potentiates mild photothermal therapy for tumor ablation.

Authors:  Zijun Jiang; Tianyi Li; Hao Cheng; Feng Zhang; Xiaoyu Yang; Shihao Wang; Jianping Zhou; Yang Ding
Journal:  Asian J Pharm Sci       Date:  2021-10-15       Impact factor: 6.598

Review 5.  Near-infrared photoresponsive drug delivery nanosystems for cancer photo-chemotherapy.

Authors:  Xiaoying Wang; Zeliang Xuan; Xiaofeng Zhu; Haitao Sun; Jingchao Li; Zongyu Xie
Journal:  J Nanobiotechnology       Date:  2020-08-03       Impact factor: 10.435

6.  Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.

Authors:  David Warther; Ying Xiao; Fangting Li; Yuqin Wang; Kristyn Huffman; William R Freeman; Michael Sailor; Lingyun Cheng
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

7.  Tailored Black Phosphorus for Erythrocyte Membrane Nanocloaking with Interleukin-1α siRNA and Paclitaxel for Targeted, Durable, and Mild Combination Cancer Therapy.

Authors:  Wenquan Ou; Jeong Hoon Byeon; Zar Chi Soe; Bo Kyun Kim; Raj Kumar Thapa; Biki Gupta; Bijay Kumar Poudel; Sae Kwang Ku; Chul Soon Yong; Jong Oh Kim
Journal:  Theranostics       Date:  2019-09-19       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.